EP2635562A1 - Dérivés de pyrrolidine utilisés en tant qu'inhibiteur de cathepsine - Google Patents

Dérivés de pyrrolidine utilisés en tant qu'inhibiteur de cathepsine

Info

Publication number
EP2635562A1
EP2635562A1 EP11776459.7A EP11776459A EP2635562A1 EP 2635562 A1 EP2635562 A1 EP 2635562A1 EP 11776459 A EP11776459 A EP 11776459A EP 2635562 A1 EP2635562 A1 EP 2635562A1
Authority
EP
European Patent Office
Prior art keywords
benzenesulfonyl
pyrrolidin
chloro
pyrimidine
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP11776459.7A
Other languages
German (de)
English (en)
Other versions
EP2635562B1 (fr
Inventor
David Banner
Uwe Grether
Wolfgang Haap
Holger Kuehne
Harald Mauser
Jean-Marc Plancher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to EP11776459.7A priority Critical patent/EP2635562B1/fr
Publication of EP2635562A1 publication Critical patent/EP2635562A1/fr
Application granted granted Critical
Publication of EP2635562B1 publication Critical patent/EP2635562B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention relates to organic compounds useful for therapy and/or prophylaxis in a mammal, and in particular to compounds that are preferential inhibitors of the cysteine protease cathepsin, in particular of the cysteine protease cathepsin S or L.
  • the invention relates in particular to a compound of formula (I)
  • R is hydrogen, alkyl, morpholinyl, haloalkylamino, alkyloxadiazolyl, hydroxyl, halopyrrolidinyl, azetidinyl, alkylamino, amino, cyanoalkylamino, halophenylalkylamino or cyanocycloalkylamino;
  • R 2 , R 3 , R 4 , R 5 and R 6 are independently selected from hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkyloxy, halogen, hydroxyl, cyanopyrazinyloxy, pyrazolyl, alkylpyrazolyl, imidazolyl, benzoimidazolyl, 6-oxo-6H-pyridazinyl, alkyl-6-oxo-6H-pyridazinyl, piperazinyl, N-alkylpiperazinyl, piperidinyl, difluoropyrrolidinyl, phenylimidazolyl, oxo-pyrrolidinyl, oxo-oxazolidinyl, morpholinyl, oxo-morpholinyl, oxo-pyridinyl, 2-oxo-2H-pyrazinyl, difluoropiperidinyl, haloal
  • a 1 is -C3 ⁇ 4-, carbonyl, -C(0)0- or absent;
  • a 2 is nitrogen or CR 7 ;
  • a 3 is nitrogen or CR £
  • a 4 is nitrogen or CR ⁇
  • R is hydrogen, alkyl, haloalkyl, halogen, hydroxyl, haloalkylaminocarbonyl; halophenylalkylaminocarbonyl, phenylcycloalkylaminocarbonyl, haloalkylphenylalkylaminocarbonyl, halophenylcycloalkylaminocarbonyl or halophenylcycloalkylalkylaminocarbonyl;
  • R is hydrogen, alkyl, haloalkyl, halogen or hydroxyl; or R 7 and R 8 together with the carbon atom to which they are attached form
  • cycloalkyl or susbsituted pyrrolidinyl wherein substituted pyrrolidinyl is pyrrolidinyl N-substituted with haloalkyl or formyl;
  • R 9 is hydrogen, alkyl, haloalkyl, halogen or nitro; or R 8 and R 9 together with the carbon atom to which they are attached form
  • the compounds of the invention are preferential inhibitors of the cysteine protease Cathepsin (Cat), in particular Cathepsin S or Cathepsin L and are therefore useful to treat metabolic diseases like diabetes, atherosclerosis, abdominal aortic aneurysm, peripheral arterial disease, cancer, reduction of cardiovascular events in chronic kidney disease, glomerulonephritis, age related macular degeneration, diabetic nephropathy and diabetic retinopathy.
  • Cat cysteine protease Cathepsin
  • immune mediated diseases like rheumatoid arthritis, Crohn's disease, multiple sclerosis, sjorgen syndrome, lupus erythematosus, neuropathic pain, diabetes type I, asthma and allergy and skin related immune disease are suitable diseases to be treated with a cathepsin S inhibitor.
  • Objects of the present invention are the compounds of formula (I) and their aforementioned salts per se and their use as therapeutically active substances, a process for the manufacture of the said compounds, intermediates, pharmaceutical compositions, medicaments containing the said compounds, their pharmaceutically acceptable salts, the use of the said compounds and salts for the prophylaxis and/or therapy of illnesses, especially in the treatment or prophylaxis of diabetes, atherosclerosis, abdominal aortic aneurysm, peripheral arterial disease, cancer, reduction of cardiovascular events in chronic kidney disease and diabetic nephropathy, and the use of the said compounds and salts for the production of medicaments for the treatment or prophylaxis of diabetes, atherosclerosis, abdominal aortic aneurysm, peripheral arterial disease, cancer, reduction of cardiovascular events in chronic kidney disease and diabetic nephropathy.
  • Mammalian cathepsins are cysteine-type proteases involved in key steps of biological and pathological events. Cathepsins are considered tractable drug targets as it is feasible to inhibit enzymatic activity with small molecules and are therefore of interest to the pharmaceutical industry (Bromme, D. (2001), 'Papain-like cysteine proteases', Curr Protoc Protein Sci, Chapter 21, Unit 21 2; Roberts, R. (2005), 'Lysosomal cysteine proteases: structure, function and inhibition of cathepsins', Drug News Perspect, 18 (10), 605-14).
  • Cathepsin S is prominently expressed in antigen presenting cells like macrophages and dendritic cells and smooth muscle cells.
  • Cathepsin S is only weakly expressed in normal arterial tissue, strong upregulation is seen in atherosclerotic arteries (Liu, J., et al. (2006), 'Increased serum cathepsin S in patients with atherosclerosis and diabetes', Atherosclerosis, 186 (2), 411-9; Sukhova, G. K., et al.
  • Cathepsin S deficient mice have a reduced atherosclerosis-phenotype when tested in appropriate mouse models.
  • LDL-Rec deficient mice reduced lipid accumulation, elastin- fibre breakdown and chronic arterial inflammation is reported.
  • APO E deficient mice a significant reduction of acute plaque rupture events was reported.
  • chronic renal disease is introduced into CatS/In APO-E deficient mice a strong reduction of accelerated calcification is seen on top of the anti atherosclerotic activity in arteries and heart valves Aikawa, E., et al.
  • Cathepsin S is involved in the degradation of extracellular matrix that stabilises the plaque.
  • Cathepsin S has potent elastinolytic activity and can exert this at neutral pH, a feature that distinguishes Cathepsin S from all other Cathepsins.
  • Cathepsin S is the major protease involved in antigen processing, in particular cleavage of the invariant chain in antigen presenting cells, resulting in reduced contribution of Tcells to the chronic inflammation of the
  • Atherosclerotic tissue Elevated inflammation results in further oxidative and proteolytic tissue damage and subsequently plaque destabilisation (Cheng, X. W., et al. (2004),
  • Cathepsin S plays also a role in the reduction of tumor growth and tumor cell invasion as described by Roberta E. Burden in Clin Cancer Res 2009;15(19).
  • nephrectomized Cathepsin S knock out mice showed a significant reduction of arterial calcification when compared to nephrectomized wild type mice. This indicates that inhibition of Cathepsin S may have a beneficial effect on the reduction of cardiovascular events in chronic kidney disease patients (Elena Aikawa, Circulation, 2009, 1785-1794).
  • Cathepsin L shows a broader expression profile than cathepsin S and there are also data which suggest a role of cathepsin L in atherosclerosis, e.g.
  • LDLrec & Cat L deficient mice show a reduced atherosclerotic phenotype (Kitamoto, S., et al. (2007), 'Cathepsin L deficiency reduces diet-induced atherosclerosis in low-density lipoprotein receptor- knockout mice', Circulation, 115 (15), 2065-75).
  • Cat L was suggested to be involved in metabolic syndrome as it controls adipogenesis and peripheral glucose tolerance.
  • Cathepsin L is described to regulate podocyte function by proteolytically processing dynamin and thereby proteinuria (Sever, S., et al.
  • alkyl signifies a straight-chain or branched-chain alkyl group with 1 to 8 carbon atoms, preferably a straight or branched-chain alkyl group with 1 to 6 carbon atoms and particularly preferred a straight or branched-chain alkyl group with 1 to 4 carbon atoms.
  • Ci-C 8 alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert- butyl, the isomeric pentyls, the isomeric hexyls, the isomeric heptyls and the isomeric octyls, preferably methyl, ethyl, propyl, isopropyl, isobutyl and tert.-butyl.
  • cycloalkyl alone or in combination, signifies a cycloalkyl ring with 3 to
  • C 3 - C 8 cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
  • Preferred cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Cyclopropyl and cyclobutyl are particularly preferred. Cyclopropyl is further preferred.
  • alkoxy signifies a group of the formula alkyl-O- in which the term “alkyl” has the previously given significance, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec. butoxy and tert.butoxy, preferably methoxy, ethoxy, propoxy and isopropoxy.
  • cycloalkyloxy alone or in combination, signifies a group of the formula cycloalkyl-O- in which the term “cycloalkyl” has the previously given significance, such as cyclobutyloxy, cyclopentyloxy or cyclohexyloxy.
  • phenyloxy alone or in combination, signifies a phenyl-O- group.
  • oxy alone or in combination, signifies the -O- group.
  • halogen or halo, alone or in combination, signifies fluorine, chlorine, bromine or iodine and preferably fluorine, chlorine or bromine, more preferably fluorine and chlorine.
  • haloalkyl denotes an alkyl group, a cycloalkyl group and an alkoxy group substituted with at least one halogen, preferably substituted with one to five halogens, preferably one to three halogens.
  • Fluoroalkyl is an alkyl group substituted with at least one fluorine atom, preferably substituted with one to five fluorine atoms, preferably one to three halogens.
  • Preferred haloalkyl are trifluoromethyl, trifluoroethyl and trifluoropropyl.
  • halophenyl denote a phenyl group, a pyrrolidinyl group, a pyridinyl group and an azetidinyl group substituted with at least one halogen, preferably substituted with one to three halogens.
  • hydroxyl and "hydroxy”, alone or in combination, signify the -OH group.
  • carbonyl alone or in combination, signifies the -C(O)- group.
  • amino alone or in combination, signifies the primary amino group (-NH 2 ), the secondary amino group (-NH-), or the tertiary amino group (-N-).
  • the salts are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, preferably hydrochloric acid, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxylic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, N-acetylcystein.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, preferably hydrochloric acid
  • organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxylic acid, maleic acid, malonic acid, succinic acid,
  • salts derived from an inorganic base include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium salts.
  • Salts derived from organic bases include, but are not limited to salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polymine resins.
  • the compound of formula (I) can also be present in the form of zwitterions.
  • Particularly preferred pharmaceutically acceptable salts of compounds of formula (I) are the salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid and methanesulfonic acid.
  • one of the starting materials or compounds of formula (I) contain one or more functional groups which are not stable or are reactive under the reaction conditions of one or more reaction steps, appropriate protecting groups (as described e.g. in "Protective
  • protecting groups can be removed at a later stage of the synthesis using standard methods described in the literature. Examples of protecting groups are tert-butoxycarbonyl (Boc), 9-fluorenylmethyl carbamate (Fmoc), 2-trimethylsilylethyl carbamate (Teoc), carbobenzyloxy (Cbz) and p-methoxybenzyloxycarbonyl (Moz).
  • the compound of formula (I) can contain several asymmetric centers and can be present in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates.
  • asymmetric carbon atom means a carbon atom with four different substituents. According to the Cahn-Ingold-Prelog Convention an asymmetric carbon atom can be of the "R” or "S" configuration.
  • the invention relates in particular to a compound of formula (I) wherein R is hydrogen, alkyl, morpholinyl, haloalkylamino, alkyloxadiazolyl, hydroxyl, halopyrrolidinyl, azetidinyl, alkylamino, amino, cyanoalkylamino, halophenylalkylamino or cyanocycloalkylamino;
  • R 2 , R 3 , R 4 , R 5 and R 6 are independently selected from hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkyloxy, halogen, hydroxyl, cyanopyrazinyloxy, pyrazolyl, alkylpyrazolyl, imidazolyl, benzoimidazolyl, 6-oxo-6H-pyridazin alkyl-6-oxo-6H-pyridazinyl, piperazinyl, N-alkylpiperazinyl, piperidinyl, difluoropyrrolidinyl, phenylimidazolyl, oxo-pyrrolidinyl, oxo-oxazolidinyl, morpholinyl, oxo-morpholinyl, oxo-pyridinyl, 2-oxo-2H-pyrazinyl, difluoropiperidinyl, haloalkylpipe
  • a 1 is -C3 ⁇ 4-, carbonyl, -C(0)0- or absent;
  • a 2 is nitrogen or CR 7 ;
  • a 3 is nitrogen or CR 8 ;
  • a 4 is nitrogen or CR 9 ;
  • R is hydrogen, alkyl, haloalkyl, halogen or hydroxyl; R is hydrogen, alkyl, haloalkyl, halogen or hydroxyl; or R 7 and R 8 together with the carbon atom to which they are attached form
  • R 9 is hydrogen, alkyl, haloalkyl or halogen; or R 8 and R 9 together with the carbon atom to which they are attached form
  • alkyl is for example methyl or ethyl.
  • haloalkylamino is for example trifluoroethylamino or trifluoropropylamino.
  • alkyloxadiazolyl is for example dimethyloxadiazolyl.
  • halopyrrolidinyl is for example difluoropyrrolidinyl.
  • alkylamino is for example ethylamino, propylamino or dimethylamino.
  • cyanoalkylamino is for example cyanomethylamino.
  • halophenylalkylamino is for example fluorophenylmethylamino.
  • cyanocycloalkylamino is for example cyanocyclopropylamino.
  • the invention also relates to a compound of formula (I) wherein R 1 is hydrogen, methyl, ethyl, morpholinyl, trifluoroethylamino, trifluoropropylamino,
  • dimethyloxadiazolyl hydroxyl, difluoropyrrolidinyl, azetidinyl, ethylamino, propylamino, dimethylamino, amino, cyanomethylamino, fluorophenylmethylamino or
  • a particular compound according to the invention is a compound of formula (I) wherein R 1 is hydrogen or amino.
  • Another particular compound according to the invention is a compound of formula (I) wherein R 2 , R 3 , R 4 , R 5 and R 6 are independently selected from hydrogen, halogen, hydroxyl, haloalkyl, cyanopyrazinyloxy, alkylpiperazinyl, hexahydro-pyrrolo[l,2- aj yrazinyl, haloalkyloxy, pyrazolyl, cycloalkylpiperazinyl, imidazolyl and alkoxyalkoxy.
  • R 2 , R 3 , R 4 , R 5 and R 6 are independently selected from hydrogen, halogen, hydroxyl, haloalkyl, cyanopyrazinyloxy, alkylpiperazinyl, hexahydro-pyrrolo[l,2- aj yrazinyl, haloalkyloxy, pyrazolyl, cycloalkylpiperazinyl, imidazolyl and al
  • R 2 and R 6 are independently selected from hydrogen, halogen and haloalkyl.
  • a compound of formula (I) wherein one of R 2 and R 6 is halogen or haloalkyl and the other one is hydrogen is another particular embodiment of the invention.
  • a compound of formula (I) wherein one of R 2 and R 6 is chloro or trifluoromethyl and the other one is hydrogen is another particular embodiment of the invention.
  • Still another particular compound of the invention is a compound of formula (I) wherein R 3 and R 5 are independently selected from hydrogen, halogen and haloalkyl. Furthermore, a particular compound of the invention is a compound of formula (I) wherein R 3 and R 5 are independently selected from hydrogen, chloro and trifluoromethyl. Moreover, a particular compound of the invention is also a compound of formula (I) wherein R 3 and R 5 are both hydrogen.
  • R 4 is hydrogen, hydroxyl, halogen,
  • cycloalkylpiperazinyl or alkoxyalkoxy is another particular embodiment of the invention.
  • the invention is also directed in particular to a compound of formula (I) wherein A 1 is absent or carbonyl.
  • the invention further relates in particular to a compound of formula (I) wherein A is CR 7 .
  • the invention is particularly concerned with a compound of formula (I) wherein A 3 is CR 8 .
  • a compound of formula (I) wherein R is hydrogen is another particular object of the invention.
  • a compound of formula (I) wherein R is hydrogen, alkyl or haloalkyl is also another particular object of the invention.
  • the invention also relates in particular to a compound of formula (I) wherein R is trifluoromethyl.
  • the invention also relates in particular to a compound of formula (I) wherein R 9 is hydrogen.
  • R 9 is hydrogen.
  • Particular compounds of formula (I) can be selected from:
  • the compounds of the present invention can be prepared, for example, by the general synthetic procedures described below.
  • R 1 to R 6 and A 1 to A 4 have, unless otherwise indicated, the meaning of R 1 to R 6 and A 1 to A 4 as defined above.
  • ACN Acetonitrile
  • BOP Benzotriazolyl-N-oxy-tris(dimethylamino)-phosphoniurn hexafluorophosphate
  • BOP-Cl Bis-(2-oxo-3-oxazolidinyl)-phosphinic acid chloride
  • CDI ⁇ , -Carbonyldiimidazole
  • DABCO 1,4-Diazabicyclo [2.2.2] octan
  • DCM Dichloromethane
  • EDCI N-(3-Dimetylaminopropyl)-N'-ethyl-carbo(iiirnide hydrochloride;
  • HATU 0-(7-azabenzotriazol-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate
  • LiHMDS Lithium bis(trimethylsilyl) amide
  • NMP N-Methylpyrrolidinone
  • Nos-Cl 3-Nitrobenzenesulfonyl chloride
  • FyBOP Benzotriazol-l-yl-oxytripyrrohdinephosphonium hexafluorophosphate
  • TEA Triethylamine
  • TBAF Tetrabutylammonium fluoride
  • TBTU 0-(Benzotriazol-l-yl)-N,N,N',N'-tetramethyluronium terafluoroborate
  • TFA Trifluoroacetic acid
  • THF Tetrahydrofurane
  • halophenylalkylamino and cyanocycloalkylamino or Rl 1 and R12 togerther with the nitrogen atom to which they are attached form morpholinyl, halopyrrolidinyl or azetidinyl.
  • An appropriate orthogonally protected 4-hydroxy proline derivative such as (2S,4R)- 4-hydroxy-pyrrolidine- 1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester or (2R,4R)-4- hydroxy-pyrrolidine- 1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester is reacted with a sulfonyl chloride such as Mes-Cl, Nos-Cl, Tos-Cl or triflic anhydride in the presence of a base such as TEA, DIEA, pyridine, etc. to yield compound 2. Reaction of 2 with thiols, in the presence of an appropriate base such as NaH, LiHMDS, DIEA, TEA, etc.
  • Oxidation of the obtained thioether is accomplished by an appropriate oxidizing agent such as H 2 O 2 , oxone, MCPBA, etc. to yield compounds 4.
  • Amide coupling is performed in presence of one of the various amide coupling reagents such as BOP-C1, TBTU, BOP, PyBop, HATU, CDI,
  • EDCI/HOBT DIC/HOBT
  • DCC/HOBT ammonium bicarbonate and di-ferf.-butyl- dicarbonat etc. to yield corresponding amide 6.
  • the protecting group PG is removed, in the case of Boc as protecting group with TFA, HC1 or formic acid in an appropriate solvent such as THF, dioxane, CH 2 CI 2 , etc. to yield compounds 7.
  • compounds 8 are oxidized to the corresponding methylsulfones 10 with e.g. H 2 O 2 , oxone, MCPBA, etc. Finally, compounds 10 are reacted with a cyanide source such as NaCN, KCN or tetrabutylammonium cyanide to yield the final compounds 11.
  • a cyanide source such as NaCN, KCN or tetrabutylammonium cyanide
  • compounds 4 can be transformed to compounds 12 by cleavage of the protecting group PG.
  • the protecting group PG is removed, in the case of Boc as protecting group with TFA, HC1 or formic acid in an appropriate solvent such as THF, dioxane, CH 2 CI 2 , etc. to yield compounds 7.
  • Subsequent amide coupling is performed in presence of one of the various amide coupling reagents such as BOP-C1, TBTU, BOP, PyBop, HATU, CDI, EDCI/HOBT, DIC/HOBT; DCC/HOBT, ammonium bicarbonate and di-ie/t.-butyl-dicarbonate etc. to yield corresponding amide 14.
  • RIO CI
  • compounds 14 are reacted with a cyanide source such as NaCN, KCN or tetrabutylammonium cyanide in the presence of an appropriate base such as DABCO, pyridine, TEA, DIEA to yield the final compounds 11.
  • a cyanide source such as NaCN, KCN or tetrabutylammonium cyanide in the presence of an appropriate base such as DABCO, pyridine, TEA, DIEA
  • RIO S-Me
  • compounds 14 are oxidized to the corresponding methylsulfones 10 with e.g. H 2 0 2 , oxone, MCPBA, etc.
  • compounds 10 are reacted with a cyanide source such as NaCN, KCN or tetrabutylammonium cyanide to yield the final compounds 11.
  • An appropriate protected 3-hydroxy pyrrolidine derivative such as (R)-3-hydroxy- pyrrolidine- 1-carboxylic acid tert-butyl ester is reacted with a sulfonyl chloride such as Mes-Cl, Nos-Cl, Tos-Cl or triflic anhydride in the presence of a base such as TEA, DIEA, pyridine, etc. to yield compound 2.
  • TBAF can be used for cleavage to yield compounds 5.
  • Reaction of compounds 5 with chloro pyridine, chloro pyrimidine and chloro pyrazine derivatives in the presence of an appropriate base such as TEA, DIEA, pyridine, Na 2 C0 3 , K 2 C0 3 , Cs 2 C0 3 and KF, NaF and CsF etc. yields compounds 6.
  • RIO CN these are the final compounds.
  • RIO CI
  • compounds 6 are reacted with a cyanide source such as NaCN, KCN or tetrabutyl- ammonium cyanide in the presence of an appropriate base such as DABCO, pyridine, TEA, DIEA to yield the final compounds 7.
  • a cyanide source such as NaCN, KCN or tetrabutyl- ammonium cyanide
  • an appropriate base such as DABCO, pyridine, TEA, DIEA
  • RIO S-Me
  • compounds 6 are oxidized to the corresponding methylsulfones 8 with e.g. H 2 O 2 , oxone, MCPBA, etc.
  • R methyl, ethyl or tert.-butyl
  • R' methyl, trifluoromethyl, 3- nitrophenyl or 4-methylphenyl
  • RIO CN or CI
  • PG Protecting group e.g. Boc, Fmoc, Cbz or Teoc.
  • An appropriate orthogonally protected 4-hydroxy proline derivative such as (2S,4R)- 4-hydroxy-pyrrolidine- 1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester or (2R,4R)-4- hydroxy-pyrrolidine- 1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester is reacted with a sulfonyl chloride such as Mes-Cl, Nos-Cl, Tos-Cl or triflic anhydride in the presence of a base such as TEA, DIEA, pyridine, etc. to yield compound 2.
  • a sulfonyl chloride such as Mes-Cl, Nos-Cl, Tos-Cl or triflic anhydride
  • a base such as TEA, DIEA, pyridine, etc.
  • Reaction of 2 with thiols, in the presence of an appropriate base such as NaH, LiHMDS, DIEA, TEA, etc yields compounds of type 3.
  • Oxidation of the obtained thioether is accomplished by an appropriate oxidizing agent such as H2O2, oxone, MCPBA, etc. to yield compounds 4.
  • Reaction of the esters 4 with hydrazine hydrate yields compounds 5.
  • the hydrazides 5 are condensed with acetic acid anhydride in the presence of hexachloroethane and a phophane derivative such as e.g. triphenyl phosphane, tricyclohexyl phosphane.
  • the protecting group PG is removed, in the case of Boc as protecting group with TFA, HC1 or formic acid in an appropriate solvent such as THF, dioxane, CH 2 CI 2 , etc. to yield compounds 7.
  • PG Fmoc
  • PG Protecting group e.g. Boc, Fmoc or Cbz
  • PGl Protecting group e.g. thexyldimethylsilyl, trimethylsilyl, tert. butyldimethylsilyl or triphenylsilyl
  • R' methyl, trifluoromethyl, 3-nitrophenyl or 4-methylphenyl
  • LG e.g. CI or Br
  • RIO CN, - SMe or CI
  • Rl 1 and R12 are independently selected from hydrogen, alkyl, haloalkylamino, hydroxyalkyl, alkylamino, amino, cyanoalkylamino, halophenylalkylamino and
  • Rl 1 and R12 togerther with the nitrogen atom to which they are attached form morpholinyl, halopyrrolidinyl, piperazinyl, alkylpiperazinyl or azetidinyl.
  • Compound 1 is then reacted with a sulfonyl chloride such as Mes-Cl, Nos-Cl, Tos-Cl or triflic anhydride in the presence of a base such as TEA, DIEA, pyridine, etc. to yield compound 2.
  • a base such as TEA, DIEA, pyridine, etc.
  • Reaction of 2 with thiols, in the presence of an appropriate base such as NaH, LiHMDS, DIEA, TEA, etc yields compounds of type 3.
  • Oxidation of the obtained thioether is accomplished by an appropriate oxidizing agent such as H 2 O 2 , Oxone,
  • the protecting group PG is removed, in the case of Boc as protecting group with TFA, HC1 or formic acid in an appropriate solvent such as THF, dioxane, CH 2 CI 2 , etc. to yield compounds 8.
  • PG Fmoc
  • Reaction of compounds 8 with chloro pyridine, chloro pyrimidine and chloro pyrazine derivatives in the presence of an appropriate base such as TEA, DIEA, pyridine, Na 2 C0 3 , K 2 C0 3 , Cs 2 C0 3 and KF, NaF and CsF etc. yields compounds 9.
  • RIO CN
  • RIO CN
  • RIO CN
  • RIO CI
  • compounds 9 are reacted with a cyanide source such as NaCN, KCN or tetrabutylammonium cyanide in the presence of an appropriate base such as DABCO, pyridine, TEA, DIEA to yield the final compounds 10.
  • R10 S-Me
  • compounds 9 are oxidized to the corresponding methylsulfones 11 with e.g. H 2 O 2 , oxone, MCPBA, etc.
  • a cyanide source such as NaCN, KCN or tetrabutylammonium cyanide to yield the final compounds 12.
  • PG Protecting group e.g. Boc, Fmoc or Cbz
  • RIO CN, -SMe or CI
  • PGl Protecting group e.g. thexyldimethylsilyl, trimethylsilyl, tert. butyldimethylsilyl or triphenylsilyl
  • R' methyl, trifluoromethyl, 3-nitrophenyl or 4-methylphenyl
  • LG e.g. CI or Br.
  • An appropriate protected 4-hydroxy-2-hydroxymethyl pyrrolidine derivative such as
  • (2R,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine-l-carboxylic acid tert-butyl ester is reacted with a silylchloride such as thexyldimethylchlorsilane, trimethylchlorosilane or tert.-butyldimethylchlorosilane in the presence of imidazole to yield compound 1.
  • a silylchloride such as thexyldimethylchlorsilane, trimethylchlorosilane or tert.-butyldimethylchlorosilane in the presence of imidazole to yield compound 1.
  • Compound 1 is then reacted with a sulfonyl chloride such as Mes-Cl, Nos-Cl, Tos-Cl or triflic anhydride in the presence of a base such as TEA, DIEA, pyridine, etc. to yield compound 2.
  • a base such as TEA, DIEA, pyridine, etc.
  • Reaction of 2 with thiols, in the presence of an appropriate base such as NaH, LiHMDS, DIEA, TEA, etc yields compounds of type 3.
  • Oxidation of the obtained thioether is accomplished by an appropriate oxidizing agent such as H 2 O 2 , oxone,
  • RIO CI
  • compounds 6 are reacted with a cyanide source such as NaCN, KCN or tetrabutylammonium cyanide in the presence of an appropriate base such as DABCO, pyridine, TEA, DIEA to yield the final compounds 7.
  • a cyanide source such as NaCN, KCN or tetrabutylammonium cyanide in the presence of an appropriate base such as DABCO, pyridine, TEA, DIEA
  • RIO -S-Me
  • compounds 6 are oxidized to the corresponding methylsulfones 8 with e.g. H 2 0 2 , oxone, MCPBA, etc.
  • compounds 8 are reacted with a cyanide source such as NaCN, KCN or tetrabutylammonium cyanide to yield the final compounds 9.
  • An appropriate protected 3 -hydroxy pyrrolidine derivative such as (R)-3 -hydroxy- pyrrolidine- 1-carboxylic acid tert-butyl ester is reacted with a sulfonyl chloride such as Mes-Cl, Nos-Cl, Tos-Cl or triflic anhydride in the presence of a base such as TEA, DIEA, pyridine, etc. to yield compound 2.
  • a base such as TEA, DIEA, pyridine, etc.
  • Reaction of 2 with thiols, in the presence of an appropriate base such as NaH, LiHMDS, DIEA, TEA, etc yields compounds of type 3.
  • Oxidation of the obtained thioether is accomplished by an appropriate oxidizing agent such as H 2 0 2 , oxone, MCPBA, etc. to yield compounds 4.
  • the protecting group PG is removed, in the case of Boc as protecting group with TFA, HC1 or formic acid in an appropriate solvent such as THF, dioxane, CH 2 C1 2 , etc. to yield compounds 5.
  • RIO CI
  • compounds 6 are reacted with a cyanide source such as NaCN, KCN or tetrabutylammonium cyanide in the presence of an appropriate base such as DABCO, pyridine, TEA, DIEA to yield compounds 7.
  • Compounds 7 are reacted with amines or alcohols or boronic acid derivatives R4-LG in the presence of a base such as TEA, DIEA, pyridine, Na 2 C0 3 , K 2 C0 3 , Cs 2 C0 3 and KF, NaF and CsF or in the presence of a base as above and a catalyst to yield the final compounds 11.
  • compounds 6 are reacted with amines or alcohols or boronic acid derivatives R4-LG in the presence of a base such as TEA, DIEA, pyridine, Na 2 C0 3 , K 2 C0 3 , Cs 2 C0 3 and KF, NaF and CsF or in the presence of a base as above and a catalyst to yield compounds 12.
  • a base such as TEA, DIEA, pyridine, Na 2 C0 3 , K 2 C0 3 , Cs 2 C0 3 and KF, NaF and CsF or in the presence of a base as above and a catalyst to yield compounds 12.
  • a base such as TEA, DIEA, pyridine, Na 2 C0 3 , K 2 C0 3 , Cs 2 C0 3 and KF, NaF and CsF or in the presence of a base as above and a catalyst to yield compounds 12.
  • Compounds 12 are oxidized to the corresponding methylsulfones 13 with e.g
  • 2,4-Dichloro-pyrimidine-5-carbonyl chloride 1 is reacted in the presence of a suitable base such as TEA, DIEA, pyridine, etc. with an amine R1-NH 2 in an appropriate solvent such as THF, DMF, ACN, dichloromethane, etc.
  • Compounds 5 are reacted with amines or alcohols or boronic acid derivatives R4-LG in the presence of a base such as TEA, DIEA, pyridine, Na 2 C0 3 , K 2 C0 3 , Cs 2 C0 3 and KF, NaF and CsF or in the presence of a base as above and a catalyst to yield the final compounds 6.
  • a base such as TEA, DIEA, pyridine, Na 2 C0 3 , K 2 C0 3 , Cs 2 C0 3 and KF, NaF and CsF or in the presence of a base as above and a catalyst to yield the final compounds 6.
  • PG protecting group as defined in scheme 1;
  • R15 is a leaving group such as F, CI, Br or I;
  • R15 F, CI, Br or I;
  • LG H, B(OH) 2 , B(OR") 2 or 4,4,5,5-Pentamethyl- [l,3,2]dioxaborolanyl;
  • catalyst e.g. copper or palladium salts with or without ligand well known in the art;
  • R4 is as defined above except hydrogen.
  • X triflate, tosylate, brosylate, nosylate, mesylate, CI, Br, I, OH (in the case of carboxylic acids), Pyrrolidine derivative 1 (synthesis described above) is reacted with amines or alcohols or boronic acid derivatives R4-LG in the presence of a base such as TEA, DIEA, pyridine, Na 2 C0 3 , K 2 C0 3 , Cs 2 C0 3 and KF, NaF and CsF or in the presence of a base as above and a catalyst to yield the compounds 2.
  • a base such as TEA, DIEA, pyridine, Na 2 C0 3 , K 2 C0 3 , Cs 2 C0 3 and KF, NaF and CsF or in the presence of a base as above and a catalyst to yield the compounds 2.
  • the protecting group PG is removed, in the case of Boc as protecting group with TFA, HC1 or formic acid in an appropriate solvent such as THF, dioxane, CH 2 C1 2 , etc. to yield compounds 3.
  • PG Fmoc
  • piperidine is used for cleavage.
  • PG Cbz
  • HBr in acetic acid or catalytic hydrogenation can be used.
  • TBAF can be used for cleavage to yield compounds 3.
  • compound 3 is reacted with a protected 2,4-dichloro-6,7-dihydro-5H- pyrrolo[3,4-d]pyrimidine in the presence of an appropriate base such as TEA, DIEA, pyridine, Na 2 C0 3 , K 2 C0 3 , Cs 2 C0 3 and KF, NaF and CsF etc. to yield compound 4.
  • the protecting group PG is removed, in the case of Boc as protecting group with TFA, HCl or formic acid in an appropriate solvent such as THF, dioxane, CH 2 CI 2 , etc. to yield compounds 5.
  • PG Fmoc, piperidine is used for cleavage.
  • PG Cbz
  • HBr in acetic acid or catalytic hydrogenation can be used.
  • PG Teoc
  • TBAF can be used for cleavage to yield compounds 5.
  • Compound 5 is subsequently reacted with alkylating or acylating agents Rl-X with methods known in the art to yield compound 6.
  • Compound 6 is reacted with a cyanide source such as NaCN, KCN or tetrabutylammonium cyanide in the presence of an appropriate base such as DABCO, pyridine, TEA, DIEA to yield final compounds 7.
  • a cyanide source such as NaCN, KCN or tetrabutylammonium cyanide
  • an appropriate base such as DABCO, pyridine, TEA, DIEA
  • the base is for example TEA, DIEA, pyridine, Na 2 C0 3 , K 2 C0 3 , Cs 2 C0 3 and KF or NaF and CsF.
  • the cyanide source is for example NaCN, KCN, potassium ferrocyanide, tetraethylammonium cyanide or tetrabutylammonium cyanide.
  • the base is for example DABCO, pyridine, lutidine, TEA or DIEA Na 2 C0 3 , K 2 C0 3 , Cs 2 C0 3 and KF or NaF and CsF.
  • the invention further relates to a compound of formula (I) for use as therapeutically active substance.
  • the invention also relates to a compound of formula (I) for use as therapeutically active substance for the treatment or prophylaxis of diabetes, atherosclerosis, abdominal aortic aneurysm, peripheral arterial disease, cancer, reduction of cardiovascular events in chronic kidney disease, diabetic nephropathy, diabetic rethinopathy or age related macular degeneration, particularly atherosclerosis, cancer, reduction of cardiovascular events in chronic kidney disease, age related macular degeneration, diabetic nephropathy or diabetic retinopathy.
  • the compounds of formula (I) and their pharmaceutically acceptable salts can be used as medicaments (e.g. in the form of pharmaceutical preparations).
  • the pharmaceutical preparations can be administered internally, such as orally (e.g.
  • the administration can also be effected parentally, such as intramuscularly or intravenously (e.g. in the form of injection solutions).
  • the compounds of formula (I) and their pharmaceutically acceptable salts can be processed with pharmaceutically inert, inorganic or organic adjuvants for the production of tablets, coated tablets, dragees and hard gelatin capsules.
  • Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc. can be used, for example, as such adjuvants for tablets, dragees and hard gelatin capsules.
  • Suitable adjuvants for soft gelatin capsules are, for example, vegetable oils, waxes, fats, semi-solid substances and liquid polyols, etc.
  • Suitable adjuvants for the production of solutions and syrups are, for example, water, polyols, saccharose, invert sugar, glucose, etc.
  • Suitable adjuvants for injection solutions are, for example, water, alcohols, polyols, glycerol, vegetable oils, etc.
  • Suitable adjuvants for suppositories are, for example, natural or hardened oils, waxes, fats, semi-solid or liquid polyols, etc.
  • the pharmaceutical preparations can contain preservatives, solubilizers, viscosity-increasing substances, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
  • the invention is also directed to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I) and a therapeutically inert carrier.
  • the invention is also concerned with the use of a compound of formula (I) for the preparation of medicaments for the treatment or prophylaxis of diabetes, atherosclerosis, abdominal aortic aneurysm, peripheral arterial disease, cancer, reduction of cardiovascular events in chronic kidney disease, diabetic nephropathy, diabetic rethinopathy or age related macular degeneration, particularly atherosclerosis, cancer, reduction of cardiovascular events in chronic kidney disease, age related macular degeneration, diabetic nephropathy or diabetic retinopathy.
  • a compound of formula (I), when manufactured according to the process of the invention is also an object of the invention.
  • the invention is also concerned with a method for the treatment or prophylaxis of diabetes, atherosclerosis, abdominal aortic aneurysm, peripheral arterial disease, cancer, reduction of cardiovascular events in chronic kidney disease, diabetic nephropathy, diabetic rethinopathy or age related macular degeneration, particularly atherosclerosis, cancer, reduction of cardiovascular events in chronic kidney disease, age related macular degeneration, diabetic nephropathy or diabetic retinopathy, which method comprises administering an effective amount of a compound of formula (I).
  • Example 1A (3.0 g) was dissolved in ACN (30 mL). 2-Chlorothiophenol (3.0 g) and TEA (2.91 mL) were added to the reaction mixture. The reaction mixture was stirred at reflux for 18 h. The reaction mixture was then quenched with water (20 mL) and extracted with ethyl acetate (200 mL) and brine (30 mL). The organic layers were dried over Na 2 S0 4 , filtrated and evaporated to dryness. The crude product was purified by flash
  • Example IB (2.06 g) was dissolved in DCM (25 mL) and cooled to 0 °C.
  • MCPBA (2.87 g) was slowly added and the reaction mixture was allowed to warm to 25 °C. The reaction mixture was stirred at 25 °C for 18 h.
  • the reaction mixture was diluted with DCM (50 mL) and extracted three times with aqueous Na 2 C0 3 solution (50 mL) and brine (50 mL). The organic layers were dried over Na 2 S0 4 , filtrated and evaporated (a peroxide test prior was negativ) to dryness to yield a light brown oil (2.06 g; 92%).
  • MS: m/z 404.0 [M+H] + .
  • Example ID (1.1 g) was dissolved in ACN (15 mL) and EDCI (703 mg), HOBT (562 mg) and DIPEA (0.62 mL) were added. The reaction mixture was stirred for 1 h at 25 °C. After that, morpholine (0.32 mL) was added and the reaction mixture was stirred at 25 °C for 18 h. After that the reaction mixture was diluted with ethyl acetate (50 mL) extracted with IN aqueous HC1 (20 mL), aqueous Na 2 C0 3 solution (20 mL) and brine (20 mL). The organic layers were dried over Na 2 S0 4 , filtrated and evaporated to dryness.
  • Example 9 was prepared in analogy to the methods described for example 1 and 2 starting from (R)-3-Hydroxy-pyrrolidine-l-carboxylic acid tert-butyl ester over (R)-3-(toluene-4- sulfonyloxy)-pyrrolidine-l-carboxylic acid tert-butyl ester to yield a amorphous brown solid.
  • MS: m/z 349.1 [M+H] + .
  • Example 12 was prepared in analogy to the methods described for example 1 starting from (R)-3-Hydroxy-pyrrolidine-l-carboxylic acid tert-butyl ester over (R)-3-(toluene-4- sulfonyloxy)-pyrrolidine-l-carboxylic acid tert-butyl ester with the exception of the last two reaction steps:
  • Example 13B 250 mg was dissolved in acetonitrile (3.5 mL) and acetic acid anhydride (79 mg) and DIEA (0.74 mL) were added. The reaction mixture was stirred for 3 h at 25 °C. After that triphenyl phosphane (649 mg) and hexachloroethane (337 mg) were added. The reaction mixture was stirred for 18 h at 25 °C. The reaction mixture was evaporated to dryness, dissolved in ethyl acetate (20 mL), extracted with water (10 mL) and brine (10 mL). The organic layers were dried over Na 2 S0 4 , filtrated and evaporated to dryness.
  • Example 26C (75 mg) was dissolved in acetonitrile (2.0 mL) and di-ie/ .-butyl-dicarbonat (48 mg) was added. After that, pyridine (0.01 mL) and ammonium bicarbonate (17 mg) were added. The reaction mixture was then stirred for 3 d at 25 °C. After that, additional ammonium bicarbonate (8 mg) and di-ie/ .-butyl-dicarbonat (24 mg) were added. The reaction mixture was was stirred at reflux for 18 h. After that, further ammonium bicarbonate (17 mg) and di-ie/t.-butyl-dicarbonat (48 mg) were added and the reaction mixture was refluxed for additional 18 h.
  • reaction mixture was diluted with ethyl acetate (20 mL) and extracted with aqueous Na 2 C0 3 (10%; 10 mL) and brine (10 mL). The organic layers were dired over Na 2 S0 4 , filtrated and evaporated to dryness to yield example 31A as a light brown oil (56 mg, 76%) which was used without further purification.
  • MS: m/z 435.3 [M+H] + .
  • Example 42
  • Example 45 4-[(S)-3-((S)-2-Chloro-4-hexahydro-pyrrolo[l,2-a]pyrazin-2-yl-benzenesulfonyl)- pyrrolidin-l-yl]-6-trifluoromethyl-pyrimidine-2-carbonitrile; compound with formic acid
  • Example 53
  • Example 54 4- ⁇ (S)-3-[2-Chloro-4-(2,2,2-trifluoro-ethoxy)-benzenesulfonyl]-pyrrolidin-l-yl ⁇ -2- cyano-pyrimidine-5-carboxylic acid (2,2,2-trifluoro-ethyl)-amide
  • Example 56 4-[(S)-3-(2-Chloro-4-imidazol-l-yl-benzenesulfonyl)-pyrrolidin-l-yl]-2-cyano- pyrimidine-5-carboxylic acid (2,2,2-trifluoro-ethyl)-amide
  • Example 57
  • reaction mixture was heated to 60 °C and stirred for 5 h.
  • the crude reaction mixture was concentrated in vacuo.
  • the reaction mixture was poured into EtOAc (25 mL) and extracted with aqueous 10% Na 2 C0 3 (2 x 20 mL) and brine.
  • the organic layers were dried over Na 2 S0 4 and concentrated in vacuo to yield a colorless viscous oil (2.48 g, 96%).
  • Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide.
  • Assay buffer 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM.
  • Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L.
  • AMC 7-Amino-4-Methyl-Coumarin.
  • Enzyme is added to the substance dilutions in 96-well microtitre plates and the reaction is started with substrate. Fluorescence emission is measured over 20 minutes, during which time a linear increase is observed in the absence of inhibitor. IC 5 0 are calculated by standard methods. Inhibition of human Cat S, mouse Cat S, human Cat K, mouse Cat K, human Cat B, mouse Cat B, human Cat L and mouse Cat L have been measured separately. The results obtained for human Cat S for representative compounds of the invention are expressed in the following table.
  • Example IC50 [uM] Example IC50 [uM]
  • the compounds according to the invention have an IC 50 which is between 0.00001 and 100 ⁇ , preferably between 0.00001 and 50 ⁇ , more preferably between 0.00001 and 20 ⁇ .
  • IC 50 which is between 0.00001 and 100 ⁇ , preferably between 0.00001 and 50 ⁇ , more preferably between 0.00001 and 20 ⁇ .
  • a compound of formula (I) can be used in a manner known per se as the active ingredient for the production of tablets of the following composition:
  • a compound of formula (I) can be used in a manner known per se as the active ingredient for the production of capsules of the following composition:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne un composé de formule (I), où A1 à A4 et R1 à R6 sont définis tels que dans la description et dans les revendications. Le composé de formule (I) peut être utilisé comme médicament.
EP11776459.7A 2010-11-05 2011-11-02 Dérivés de pyrrolidine commes inhibiteurs de la cathepsin Not-in-force EP2635562B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11776459.7A EP2635562B1 (fr) 2010-11-05 2011-11-02 Dérivés de pyrrolidine commes inhibiteurs de la cathepsin

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10190239 2010-11-05
PCT/EP2011/069219 WO2012059507A1 (fr) 2010-11-05 2011-11-02 Dérivés de pyrrolidine utilisés en tant qu'inhibiteur de cathepsine
EP11776459.7A EP2635562B1 (fr) 2010-11-05 2011-11-02 Dérivés de pyrrolidine commes inhibiteurs de la cathepsin

Publications (2)

Publication Number Publication Date
EP2635562A1 true EP2635562A1 (fr) 2013-09-11
EP2635562B1 EP2635562B1 (fr) 2014-09-03

Family

ID=43645895

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11776459.7A Not-in-force EP2635562B1 (fr) 2010-11-05 2011-11-02 Dérivés de pyrrolidine commes inhibiteurs de la cathepsin

Country Status (12)

Country Link
US (1) US8524710B2 (fr)
EP (1) EP2635562B1 (fr)
JP (1) JP5670580B2 (fr)
KR (1) KR101522119B1 (fr)
CN (1) CN103201274B (fr)
AR (1) AR083700A1 (fr)
BR (1) BR112013010699A2 (fr)
CA (1) CA2815611C (fr)
ES (1) ES2512445T3 (fr)
MX (1) MX346090B (fr)
RU (1) RU2548684C2 (fr)
WO (1) WO2012059507A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2014136573A (ru) 2012-02-17 2016-04-10 Ф. Хоффманн-Ля Рош Аг Новые производные пирролидина
CA2870527A1 (fr) * 2012-04-17 2013-10-24 Astellas Pharma Inc. Compose heterocyclique aromatique bicyclique azote
EP3055314B1 (fr) * 2013-10-08 2018-09-12 Merck Sharp & Dohme Corp. Inhibiteurs de cysteine protease de type cathepsine
EP3174879B1 (fr) * 2014-08-01 2018-07-18 Boehringer Ingelheim International GmbH Oxétanes substitués et leur utilisation en tant qu'inhibiteurs de la cathépsine c
JOP20190181B1 (ar) 2017-01-24 2023-09-17 Astellas Pharma Inc مركب برولين أميد به استبدال بواسطة فينيل داي فلوروميثيل
WO2024099403A1 (fr) * 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 Composé thioéther ayant une propriété de médicament doux et son utilisation, composition pharmaceutique et utilisation associées

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU783145B2 (en) 1999-12-24 2005-09-29 F. Hoffmann-La Roche Ag Nitrile derivatives as cathepsin K inhibitors
AR036375A1 (es) * 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
SE0201976D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
TW200745055A (en) * 2005-09-23 2007-12-16 Organon Nv 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
JP2010508322A (ja) * 2006-10-30 2010-03-18 グラクソ グループ リミテッド システインプロテアーゼ阻害薬としての新規置換ピリジン誘導体
PL2421826T3 (pl) 2009-04-20 2014-03-31 Hoffmann La Roche Pochodne proliny jako inhibitory katepsyn

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2012059507A1 *

Also Published As

Publication number Publication date
RU2548684C2 (ru) 2015-04-20
CN103201274A (zh) 2013-07-10
KR20130089265A (ko) 2013-08-09
AR083700A1 (es) 2013-03-13
CA2815611A1 (fr) 2012-05-10
RU2013124993A (ru) 2014-12-10
JP5670580B2 (ja) 2015-02-18
US20120115843A1 (en) 2012-05-10
MX2013004667A (es) 2013-06-28
CA2815611C (fr) 2015-12-29
US8524710B2 (en) 2013-09-03
JP2013541574A (ja) 2013-11-14
WO2012059507A1 (fr) 2012-05-10
KR101522119B1 (ko) 2015-05-20
EP2635562B1 (fr) 2014-09-03
ES2512445T3 (es) 2014-10-24
CN103201274B (zh) 2014-08-20
BR112013010699A2 (pt) 2016-08-09
MX346090B (es) 2017-03-07

Similar Documents

Publication Publication Date Title
CA2758210C (fr) Derives de proline comme inhibiteurs de la cathepsine
EP2635562B1 (fr) Dérivés de pyrrolidine commes inhibiteurs de la cathepsin
JP6322646B2 (ja) Ｃｂ２受容体アゴニストとしての新規ピラジン誘導体
EP1591443B1 (fr) Derive de pyrazole
MX2008010899A (es) Piperidinoilpirrolidinas agonistas del receptor de melanocortina tipo 4.
US11858924B2 (en) N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides
EP2814822A1 (fr) Nouveaux dérivés de pyrrolidine
JP6096808B2 (ja) 新規なアゼチジン誘導体
TW201302724A (zh) 新穎吡咯啶衍生物
RU2825000C2 (ru) Класс бифункциональных химерных гетероциклических соединений для направленного разрушения андрогенных рецепторов и их применение

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130605

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140326

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PLANCHER, JEAN-MARC

Inventor name: GRETHER, UWE

Inventor name: HAAP, WOLFGANG

Inventor name: MAUSER, HARALD

Inventor name: KUEHNE, HOLGER

Inventor name: BANNER, DAVID

INTG Intention to grant announced

Effective date: 20140411

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 685530

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140915

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602011009686

Country of ref document: DE

Effective date: 20141016

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2512445

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20141024

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 685530

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140903

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140903

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141203

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140903

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141204

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140903

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20140903

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140903

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140903

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140903

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140903

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140903

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140903

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140903

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140903

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150105

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140903

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140903

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150103

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140903

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602011009686

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141102

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140903

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141130

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140903

26N No opposition filed

Effective date: 20150604

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140903

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140903

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140903

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140903

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140903

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20111102

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20171130

Year of fee payment: 7

Ref country code: FR

Payment date: 20171018

Year of fee payment: 7

Ref country code: TR

Payment date: 20171030

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20171207

Year of fee payment: 7

Ref country code: GB

Payment date: 20171026

Year of fee payment: 7

Ref country code: CH

Payment date: 20171025

Year of fee payment: 7

Ref country code: IT

Payment date: 20171113

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140903

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140903

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602011009686

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20181102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181130

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181130

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190601

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181102

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20200102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181103

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181102